Low-dose CT screening for lung cancer
In the National Lung Screening Trial, annual low-dose CT screening of people at high risk from smoking reduced lung-cancer mortality compared with chest X-ray.
What the study found
The National Lung Screening Trial (New England Journal of Medicine, 2011) randomly assigned more than 50,000 people at high risk for lung cancer — older adults with heavy smoking histories — to three annual screens with either low-dose computed tomography (CT) or standard chest X-ray. The low-dose CT group had a roughly 20 percent lower rate of death from lung cancer, because CT detected more cancers at an earlier, more treatable stage than X-ray could.
Why it matters
Lung cancer is often found late, when it is hard to treat, which is a major reason it causes so many deaths. NLST provided the first strong randomized evidence that a screening test could lower lung-cancer mortality in a defined high-risk group, and it underpins current recommendations that such screening be considered for eligible people.
Analysis — the pattern
This reflects a general screening principle (analysis, not a single-study claim): screening tends to help most when it is aimed at people whose risk is high enough that the benefits outweigh the harms. Those harms are real — false alarms, follow-up procedures, and overdiagnosis of cancers that might never have caused harm — which is why eligibility is defined narrowly rather than offered to everyone.
What is still uncertain
The benefit was shown in a specific high-risk population, and extending screening too broadly can shift the balance toward harm. Optimal screening intervals, how to manage the many benign nodules CT finds, and how to reach eligible people equitably remain active questions.